WPD Pharmaceuticals Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a WBIO.CN research report →
Companywww.wpdpharmaceuticals.com
WPD Pharmaceuticals Inc. engages in the research and development of medicinal products in the fields of oncology and infectious diseases. Its drug development pipeline includes WPD101 to treat brain cancers, including glioblastoma that is in the pre-clinical trial; WPD102 to treat Uval Melanoma, which is in the pre-clinical trial; Berubicin for the treatment of glioblastoma that us in phase 1 clinical trial; and WP1066 to treat central nervous system tumors, pancreatic cancer, and ocular tumors, which is in phase 1 clinical trial.
- CEO
- Mariusz Olejniczak
- IPO
- 2009
- Employees
- 16
- HQ
- Vancouver, BC, CA
Price Chart
Valuation
- Market Cap
- $324.76K
- P/E
- -99.29
- P/S
- 0.00
- P/B
- -14.30
- EV/EBITDA
- -13.43
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 15.48%
- ROIC
- 106.68%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-80,082 · -102.08%
- EPS
- $-0.00 · -102.06%
- Op Income
- $-268,910
- FCF YoY
- 94.08%
Performance & Tape
- 52W High
- $1.13
- 52W Low
- $0.07
- 50D MA
- $0.18
- 200D MA
- $0.23
- Beta
- 0.14
- Avg Volume
- 761
Get TickerSpark's AI analysis on WBIO.CN
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our WBIO.CN Coverage
We haven't published any research on WBIO.CN yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate WBIO.CN Report →